[COPD - An Underestimated Disease].

Leuppi, Jörg D; Bridevaux, Pierre-Olivier; Charbonnier, Florian; Clarenbach, Christian F; Duchna, Hans-Werner; Fellrath, Jean-Marc; Gianella, Pietro; Jochmann, Anja; Kern, Lukas; Pavlov, Nikolay; Rothe, Thomas; Steurer-Stey, Claudia; von Garnier, Christophe (2023). [COPD - An Underestimated Disease]. Praxis, 112(7-8), pp. 403-412. Hogrefe 10.1024/1661-8157/a004049

Preview

Text 1661-8157_a004049.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (389kB) | Preview

COPD - An Underestimated Disease Abstract: Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition with a complex clinical picture. The diagnosis is not easy to make because COPD can develop insidiously and remain unnoticed for a long time. Therefore, general practitioners play a central role in the early detection of the disease. Suspected COPD can be confirmed by special examinations in collaboration with pulmonologists. The new GOLD guideline defines three COPD risk groups (A-B-E) which should guide the personalized treatment concept. A short- or long-acting bronchodilator (SAMA/SABA or LAMA/LABA) is recommended for group A, and a dual long-acting bronchodilator therapy (LABA+LAMA) is recommended for group B and E. In case of blood eosinophilia (≥300 cells/µl) and/or recent hospitalization for COPD exacerbation, triple therapy (LABA+LAMA+ICS) is recommended. General practitioners are important in implementing non-pharmacological measures (smoking cessation, regular exercise, vaccinations, patient selfmanagement education). However, this also underlines the high demands of the implementation of the GOLD guideline in daily practice.

Interest & Impact

Downloads

0 since deposited on 07 Jun 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item